Earlier on January 21, RBC Capital analyst Leonid Timashev raised the price target for Nuvation Bio to $12 from $9 with an ...
The restricted stock units will vest in equal annual installments over four years, subject to each individual's continued service with TELA Bio through the applicable vesting dates. About TELA Bio, ...
The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.
Nuvation Bio Inc. (NYSE:NUVB) is one of the Stocks to Buy Under $10 with High Potential. On January 15, Soumit Roy from JonesTrading reiterated a Buy rating on the stock and raised the price target ...
Fintel on MSN
B of A Securities initiates coverage of Belite Bio, Inc - Depositary Receipt (BLTE) with buy recommendation
Fintel reports that on January 26, 2026, B of A Securities initiated coverage of Belite Bio, Inc - Depositary Receipt (NasdaqCM:BLTE) with a Buy recommendation. Analyst Price Forecast Suggests 14.84% ...
New capabilities mark continued momentum as company advances discovery research applications and accelerates the global growth of its spatial biology business Takara Bio USA, Inc. (“Takara Bio USA”), ...
Climb Bio appointed Dr. Perrin Wilson as Chief Business Officer to strengthen its leadership in developing immune-mediated disease treatments. Climb Bio, Inc. has announced the appointment of Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results